Business
Veru Announces Appointment of Jason Davies to Lead EMEA, LATAM and APAC Infectious Disease Franchise for Veru International Focused on Hospitalized COVID-19 Patients
MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other
About this update from Veru Inc.
[{"type":"text","content":"MIAMI, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Jason Davies as Executive Vice President – General Manager of Europe, the Middle East and Africa (EMEA), Latin America (LATAM), and Asia Pacific (APAC) for Veru’s Infectious Disease Franchise for Veru International. Most recently Mr. Davies had been the EMEA Head of Launch Excellence – Pharmaceutical Portfolio at Janssen (Johnson & Johnson) where he was responsible for creating and leading a new organization to enhance launch strategy and execution across all of Janssen’s EMEA pharmaceutical portfolio. Prior to this role, Mr. Davies had spent approximately 20 years in a number of commercial positions of increasing responsibility spread across Janssen’s business units, including pharmaceutical business unit P&L responsibility, sales, marketing, market access, integration and strategy, with a focus on pharmaceuticals for virology/infectious disease and many other therapeutic areas. “Jason is an accomplished experienced commercial leader with extensive knowledge in viral infectious disease product commercialization and ex-U.S. product launches,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru Inc. “We are excited to have Jason join Veru at this critical juncture. Jason will be the head of our newly formed EMEA, LATAM and APAC Infectious Disease Franchise for Veru International and he will be responsible for developing and leading all aspects of our international governments advanced purchase agreement efforts as well as our go-to-market strategy for sabizabulin for COVID-19, if authorized, as well as planned future indications for other viral and ARDS-related and inflammatory diseases.” About Veru Inc.Veru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers. Infectious disease program: The Company has completed a positive Phase 3 COVID-19 study in hospitalized moderate to severe COVID-19 patients at substantial risk for ARDS. A double-blind, randomized, placebo-controlled Phase 3 COVID-19 clinical t...